The Neuroshield Study

The Neuroshield Study is investigating a new medication aimed at treating a rare autoimmune brain disease. This disorder disrupts the brain’s ability to communicate with the rest of the body. The study drug is designed to restore healthy brain function by blocking harmful antibodies from binding to NMDA receptors. It is administered via an intravenous infusion (IV) over approximately 90 minutes.

This potential treatment acts as a protective shield for the brain. The brain relies on NMDA receptors, special proteins that control electrical signals. Think of these receptors as tiny gates that only open when they receive the right key, allowing specific signals to pass through brain cells. NMDA receptors are essential for brain functions like memory and learning. In some people, the immune system mistakenly attacks these receptors, causing brain inflammation, a condition known as Anti-NMDA Receptor Encephalitis (ANRE).

This study is exploring promising medications that could potentially treat and reverse the effects of this rare immune-related disease. Participants will be compensated for their time in completing the study.

The trial has been approved by an independent ethics committee.

Call us on 1800 243 733 to discuss your eligibility today!